Peregrine Ventures Invest USD 2.2 Million in OutSense

November 9th 2020

Israel's leading VC fund, Peregrine Ventures, has completed a USD 2.2 million Series A financing round with OutSense, who intends to use the funds to continue developing technology to monitor health and prevent potentially life-threatening disease. OutSense's "proprietary technology includes screening for hidden blood in stool, which is an established early sign of colorectal cancer (CRC). The technology also monitors dehydration, urinary tract infections, constipation, and diarrhea, which are major causes for hospitalization of the elderly".

Peregrine Ventures is represented by Elie Sprung, Head of Hi-Tech and Venture Capital.

Read more about the financing round here.

This website uses cookies

We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You consent to our cookies if you continue to use our website.
OK Read more